207 related articles for article (PubMed ID: 23701393)
21. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ; Stevens TW; Eshuis EJ; Gardenbroek TJ; Bosmans JE; van Dongen JM; Mol B; Buskens CJ; Stokkers PCF; Hart A; D'Haens GR; Bemelman WA; Ponsioen CY;
Gut; 2019 Oct; 68(10):1774-1780. PubMed ID: 31233395
[TBL] [Abstract][Full Text] [Related]
22. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
[TBL] [Abstract][Full Text] [Related]
23. Incorrect cost of infliximab in fistulizing Crohn's disease.
Lichtenstein GR
Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614
[No Abstract] [Full Text] [Related]
24. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
25. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
26. Health care resource use and costs in Crohn's disease before and after infliximab therapy.
Loomes DE; Teshima C; Jacobs P; Fedorak RN
Can J Gastroenterol; 2011 Sep; 25(9):497-502. PubMed ID: 21912761
[TBL] [Abstract][Full Text] [Related]
27. Infliximab and surgical treatment of complex anal Crohn's disease.
Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
[TBL] [Abstract][Full Text] [Related]
28. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
Dig Dis Sci; 2015 Sep; 60(9):2762-70. PubMed ID: 25673037
[TBL] [Abstract][Full Text] [Related]
29. Resource use in patients with Crohn's disease treated with infliximab.
Saro C; da la Coba C; Casado MA; Morales JM; Otero B
Aliment Pharmacol Ther; 2007 Nov; 26(10):1313-23. PubMed ID: 17850419
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
[No Abstract] [Full Text] [Related]
31. Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint.
Hilsden R
Can J Gastroenterol; 2002 Dec; 16(12):865-8. PubMed ID: 12522477
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
34. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease.
Mitton CR;
Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
[TBL] [Abstract][Full Text] [Related]
36. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
De Greef E; Hoffman I; D'Haens G; Van Biervliet S; Smets F; Scaillon M; Dewit O; Peeters H; Paquot I; Alliet P; Arts W; Hauser B; Vermeire S; Van Gossum A; Rahier JF; Etienne I; Louis E; Coche JC; Mahachie John J; Van Steen K; Veereman G; ;
Acta Gastroenterol Belg; 2012 Dec; 75(4):425-31. PubMed ID: 23402086
[TBL] [Abstract][Full Text] [Related]
37. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
[TBL] [Abstract][Full Text] [Related]
38. Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease.
Stein DJ; Ananthakrishnan AN; Issa M; Williams JB; Beaulieu DB; Zadvornova Y; Ward A; Johnson K; Knox JF; Skaros S; Binion DG
Inflamm Bowel Dis; 2010 Jul; 16(7):1173-9. PubMed ID: 19924800
[TBL] [Abstract][Full Text] [Related]
39. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
40. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
